Angiogenesis blockade as a new therapeutic approach to experimental colitis

Gut

Volumn 56, Issue 6, 2007, Pages 855-862

  Danese, Silvio ^a   Sans, Miquel ^b   Spencer, David M ^c   Beck, Ivy ^d   Doñate, Fernando ^d   Plunkett, Marian L ^d   De La Motte, Carol ^e   Redline, Raymond ^c   Shaw, David E ^f   Levine, Alan D ^c   Mazar, Andrew P ^d   Fiocchi, Claudio ^e  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Attenuon LLC   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f D E SHAW RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ATN 161; DEXTRAN; INTERLEUKIN 10; SODIUM SULFATE; THYMIDINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HOUSING; IMMUNOMODULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; STAINING;

ACUTE DISEASE; ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INTERLEUKIN-10; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES;

EID: 34249801207     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.114314     Document Type: Article

References (52)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
4. Gould VE, Wagner BM. Angiogenesis: an expanding universe. Hum Pathol 2002;33:1061-3.
5. Majno G. Chronic inflammation: links with angiogenesis and wound healing. Am J Pathol 1998;153:1035-9.
6. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
7. Bagli E, Xagorari A, Papetropoulos A, et al. Angiogenesis in inflammation. Autoimmun Rev 2004;3(Suppl 1):S26.
8. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 1999;103:3-4.
9. Szekanecz Z, Koch AE. Vascular endothelium and immune responses: implications for inflammation and angiogenesis. Rheum Dis Clin North Am 2004;30:97-114.
10. Jackson JR, Seed MP, Kircher CH, et al. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11:457-65.
11. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006;130:2060-73.
12. Wilder RL. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 2002;61(Suppl 2):ii96-9.
13. Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol 1996:69-87.
14. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-30.
15. Everts M, Scharaa AJ, de Leij LF, et al. In:, Molema G, Meijer DKF, eds. Vascular endothelium in inflamed tissue as a target for site selective delivery of drugs. Weinheim: Viley-VCH, 2001:171-97.
16. Klein S, de Fougerolles AR, Blaikie P, et al. Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002;22:5912-22.
17. Takahashi H, Soderstrom K, Nilsson E, et al. Integrins and other adhesion molecules on lymphocytes from synovial fluid and peripheral blood of rheumatoid arthritis patients. Eur J Immunol 1992;22:2879-85.
18. Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003;104:496-503.
19. Cianfrocca ME, Kimmel KA, Gallo J, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer 2006;94:1621-6.
20. Spencer DM, Veldman GM, Banerjee S, et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002;122:94-105.
21. Vowinkel T, Kalogeris TJ, Mori M, et al. Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 2004;49:556-64.
22. Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006;176:2617-24.
23. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.
24. Vermeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996;32A: 2474-84.
25. Danese S, Katz J, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;10:1435-41.
26. Sturm A, Leite AZ, Danese S, et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 2004;53:1624-31.
27. McLaren WJ, Anikijenko P, Thomas SG, et al. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci 2002;47:2424-33.
28. Liu ES, Ye YN, Shin VY, et al. Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis 2003;24:1407-13.
29. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nat Med 2003;9:713-25.
30. Romagnani P, Lasagni L, Annunziato F, et al. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004;25:201-9.
31. Libby P, Zhao DX. Allograft arteriosclerosis and immune-driven angiogenesis. Circulation 2003;107:1237-9.
32. Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis 2000;59(Suppl 1):i65-71.
33. Creamer D, Sullivan D, Bicknell R, et al. Angiogenesis in psoriasis. Angiogenesis 2002;5:231-6.
34. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004;10:1095-103.
35. Moulton KS, Heller E, Konerding MA, et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32.
36. Hammes H-P, Brownlee M, Joncyzk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996;2:529-33.
37. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
38. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J 2000;6(Suppl 3):S245-9.
39. Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 2005;4:3-8.
40. Kumar CC. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4:123-31.
41. Kim S, Harris M, Varner JA. Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 2000;275:33920-8.
42. Chidlow JH, Langston W, Greer JJM, et al. Differential Angiogenic regulation of experimental colitis. Am J Pathol 2006;169:2014-30.
43. Yamashita A, Yonemitsu Y, Okano S, et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002;168:450-7.
44. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8.
45. Khurana R, Zhuang Z, Bhardwaj S, et al. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 2004;110:2436-43.
46. Storgard CM, Stupack DG, Jonczyk A, et al. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999;103:47-54.
47. Wilson JF. Angiogenesis therapy moves beyond cancer. Ann Intern Med 2004;141:165-8.
48. Canete JD, Pablos JL, Sanmarti R, et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum 2004;50:1636-41.
49. Walsh DA, Pearson CI. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 2001;3:147-53.
50. Moulton KS, Vakili K, Zurakowski D, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100:4736-41.
51. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004;6:R326- 34.
52. Dredge K, Dalgleish AG, Marriott JB. Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs 2003;4:667-74.